Literature DB >> 31434712

ADAMDEC1 Maintains a Growth Factor Signaling Loop in Cancer Stem Cells.

Ana Jimenez-Pascual1, James S Hale2,3, Anja Kordowski1, Jamie Pugh1, Daniel J Silver4,3, Defne Bayik4,3, Gustavo Roversi4, Tyler J Alban4,3,5, Shilpa Rao4,3, Rui Chen4, Thomas M McIntyre4,3,5, Giorgio Colombo6, Giulia Taraboletti7, Karl O Holmberg8, Karin Forsberg-Nilsson8, Justin D Lathia2,3,5, Florian A Siebzehnrubl9.   

Abstract

Glioblastomas (GBM) are lethal brain tumors where poor outcome is attributed to cellular heterogeneity, therapeutic resistance, and a highly infiltrative nature. These characteristics are preferentially linked to GBM cancer stem cells (GSC), but how GSCs maintain their stemness is incompletely understood and the subject of intense investigation. Here, we identify a novel signaling loop that induces and maintains GSCs consisting of an atypical metalloproteinase, ADAMDEC1, secreted by GSCs. ADAMDEC1 rapidly solubilizes FGF2 to stimulate FGFR1 expressed on GSCs. FGFR1 signaling induces upregulation of ZEB1 via ERK1/2 that regulates ADAMDEC1 expression through miR-203, creating a positive feedback loop. Genetic or pharmacologic targeting of components of this axis attenuates self-renewal and tumor growth. These findings reveal a new signaling axis for GSC maintenance and highlight ADAMDEC1 and FGFR1 as potential therapeutic targets in GBM. SIGNIFICANCE: Cancer stem cells (CSC) drive tumor growth in many cancers including GBM. We identified a novel sheddase, ADAMDEC1, which initiates an FGF autocrine loop to promote stemness in CSCs. This loop can be targeted to reduce GBM growth.This article is highlighted in the In This Issue feature, p. 1469. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31434712      PMCID: PMC7400732          DOI: 10.1158/2159-8290.CD-18-1308

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  56 in total

Review 1.  The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?

Authors:  Simone Brabletz; Thomas Brabletz
Journal:  EMBO Rep       Date:  2010-08-13       Impact factor: 8.807

2.  Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression.

Authors:  Alvaro G Alvarado; Praveena S Thiagarajan; Erin E Mulkearns-Hubert; Daniel J Silver; James S Hale; Tyler J Alban; Soumya M Turaga; Awad Jarrar; Ofer Reizes; Michelle S Longworth; Michael A Vogelbaum; Justin D Lathia
Journal:  Cell Stem Cell       Date:  2017-01-12       Impact factor: 24.633

3.  Molecular signatures classify astrocytic gliomas by IDH1 mutation status.

Authors:  Grischa Toedt; Sebastian Barbus; Marietta Wolter; Jörg Felsberg; Björn Tews; Frederic Blond; Michael C Sabel; Stefanie Hofmann; Natalia Becker; Christian Hartmann; Hiroko Ohgaki; Andreas von Deimling; Otmar D Wiestler; Meinhard Hahn; Peter Lichter; Guido Reifenberger; Bernhard Radlwimmer
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

4.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Authors:  Michael Weller; Nicholas Butowski; David D Tran; Lawrence D Recht; Michael Lim; Hal Hirte; Lynn Ashby; Laszlo Mechtler; Samuel A Goldlust; Fabio Iwamoto; Jan Drappatz; Donald M O'Rourke; Mark Wong; Mark G Hamilton; Gaetano Finocchiaro; James Perry; Wolfgang Wick; Jennifer Green; Yi He; Christopher D Turner; Michael J Yellin; Tibor Keler; Thomas A Davis; Roger Stupp; John H Sampson
Journal:  Lancet Oncol       Date:  2017-08-23       Impact factor: 41.316

5.  Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.

Authors:  Lan B Hoang-Minh; Florian A Siebzehnrubl; Changlin Yang; Silveli Suzuki-Hatano; Kyle Dajac; Tyler Loche; Nicholas Andrews; Michael Schmoll Massari; Jaimin Patel; Krisha Amin; Alvin Vuong; Ana Jimenez-Pascual; Paul Kubilis; Timothy J Garrett; Craig Moneypenny; Christina A Pacak; Jianping Huang; Elias J Sayour; Duane A Mitchell; Matthew R Sarkisian; Brent A Reynolds; Loic P Deleyrolle
Journal:  EMBO J       Date:  2018-10-15       Impact factor: 11.598

6.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens.

Authors:  Steven M Pollard; Koichi Yoshikawa; Ian D Clarke; Davide Danovi; Stefan Stricker; Roslin Russell; Jane Bayani; Renee Head; Marco Lee; Mark Bernstein; Jeremy A Squire; Austin Smith; Peter Dirks
Journal:  Cell Stem Cell       Date:  2009-06-05       Impact factor: 24.633

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Glioblastoma cell growth is suppressed by disruption of Fibroblast Growth Factor pathway signaling.

Authors:  Watcharin Loilome; Avadhut D Joshi; Colette M J ap Rhys; Sara Piccirillo; Angelo L Vescovi; Vescovi L Angelo; Gary L Gallia; Gregory J Riggins
Journal:  J Neurooncol       Date:  2009-04-02       Impact factor: 4.130

10.  Identification of a cancer stem cell in human brain tumors.

Authors:  Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

View more
  27 in total

Review 1.  Metabolic heterogeneity and adaptability in brain tumors.

Authors:  Christian E Badr; Daniel J Silver; Florian A Siebzehnrubl; Loic P Deleyrolle
Journal:  Cell Mol Life Sci       Date:  2020-06-06       Impact factor: 9.261

2.  Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma.

Authors:  Jintao Gu; Nan Mu; Bo Jia; Qingdong Guo; Luxiang Pan; Maorong Zhu; Wangqian Zhang; Kuo Zhang; Weina Li; Meng Li; Lichun Wei; Xiaochang Xue; Yingqi Zhang; Wei Zhang
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

Review 3.  The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions.

Authors:  Kelly Mitchell; Katie Troike; Daniel J Silver; Justin D Lathia
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

Review 4.  FGF2: a novel druggable target for glioblastoma?

Authors:  Ana Jimenez-Pascual; Kelly Mitchell; Florian A Siebzehnrubl; Justin D Lathia
Journal:  Expert Opin Ther Targets       Date:  2020-03-16       Impact factor: 6.797

5.  Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules.

Authors:  Yasuyo Sano; Toshimi Yoshida; Min-Kyung Choo; Yanek Jiménez-Andrade; Kathryn R Hill; Katia Georgopoulos; Jin Mo Park
Journal:  Mol Cancer Res       Date:  2020-11-24       Impact factor: 6.333

6.  Sex- and mutation-specific p53 gain-of-function activity in gliomagenesis.

Authors:  Nathan C Rockwell; Wei Yang; Nicole M Warrington; Max V Staller; Malachi Griffith; Obi L Griffith; Christina A Gurnett; Barak A Cohen; Dustin Baldridge; Joshua B Rubin
Journal:  Cancer Res Commun       Date:  2021-12

Review 7.  Cancer stem cells in esophageal squamous cell cancer.

Authors:  Qian Wu; Zhe Wu; Cuiyu Bao; Wenjing Li; Hui He; Yanling Sun; Zimin Chen; Hao Zhang; Zhifeng Ning
Journal:  Oncol Lett       Date:  2019-09-20       Impact factor: 2.967

Review 8.  The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells.

Authors:  David Bakhshinyan; Neil Savage; Sabra Khalid Salim; Chitra Venugopal; Sheila K Singh
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

9.  Comprehensive analysis of macrophage-related multigene signature in the tumor microenvironment of head and neck squamous cancer.

Authors:  Bo Lin; Hao Li; Tianwen Zhang; Xin Ye; Hongyu Yang; Yuehong Shen
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

Review 10.  Proteases Regulate Cancer Stem Cell Properties and Remodel Their Microenvironment.

Authors:  Anamarija Habič; Metka Novak; Bernarda Majc; Tamara Lah Turnšek; Barbara Breznik
Journal:  J Histochem Cytochem       Date:  2021-07-26       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.